PHENYLKETONURIA AND THE PHENYLALANINEMIAS OF INFANCY

PEDIATRICS ◽  
1972 ◽  
Vol 49 (4) ◽  
pp. 628-629
Author(s):  
Robert B. Kugel ◽  
John Bowman Bartran ◽  
Roger B. Bost ◽  
James J. A. Cavanaugh ◽  
Virgil Hanson ◽  
...  

In 1965 this Committee issued a statement outlining the responsibilities of the physician to the child with phenylketonuria, an inherited abnormality of amino acid metabolism. A lack of knowledge about the disorder and about the results of treatment placed constraints on the 1965 statement. The Committee therefore feels that, with recent advances in knowledge about the disorder, a new statement is needed. An increased level of phenylalanine in the blood can occur under sporadic and transient conditions in the absence of disease, with or without a concomitant elevation of serum tyrosine; it is always present in the disorder now called phenylketonuria. Because of incomplete information, simple classification of a specific case of phenylalaninemia is often not possible. Screening programs allow for the detection of infants with elevated blood levels of phenylalanine. Screening programs should be encouraged and supported because they are the best available means for identifying all infants with abnormalities of protein metabolism resulting in serum phenylalanine elevations. Two important, unresolved issues need clarification: (1) the effect of a persistently elevated blood level of phenylalanine on the intellectual growth of the child when there are no other indications of disease, and (2) the possibility of harmful effects of a diet low in phenylalanine. The basic treatment of phenylketonuria is to reduce circulating phenylalanine by dietary restriction; and, because a spectrum of disorders causes an elevation of that amino acid, differing approaches in management seem indicated. The relative rarity of phenylketonuria precludes the opportunity for individual physicians to gain widespread experience and expertise in management outside of a hospital specialty clinic setting.

PEDIATRICS ◽  
1967 ◽  
Vol 39 (2) ◽  
pp. 297-308
Author(s):  
John H. Menkes

It is clear that, although further screening programs of neurologically defective subjects are bound to uncover more unusual defects in intermediary metabolism, we are still at a loss to explain the pathogenesis for the cerebral abnormality in the most common of the amino acid disorders. It is likely that no single answer will be found but rather that cerebral malfunction is the outcome of a number of chemical abnormalities occurring within the brain as a consequence of a deranged internal milieu present during a critical phase of its development. However, until we obtain a better concept of the abnormalities in the chemical composition and structure of the brain which occur in these conditions and the specific intermediary metabolite or metabolites responsible for them, treatment for these disorders will of necessity continue to be empirical.


1979 ◽  
Vol 7 (1) ◽  
pp. 261-262
Author(s):  
E. V. ROWSELL

1985 ◽  
Vol 4 ◽  
pp. 141-146 ◽  
Author(s):  
K VESTERBERG ◽  
J BERGSTROM ◽  
P FURST ◽  
U LEANDER ◽  
E VINNARS

Diabetes ◽  
1993 ◽  
Vol 42 (12) ◽  
pp. 1868-1877 ◽  
Author(s):  
L. Luzi ◽  
A. S. Petrides ◽  
R. A. De Fronzo

Sign in / Sign up

Export Citation Format

Share Document